Participant flow

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) · Source last updated 2023-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants randomized to this arm received the study drug, tivozanib hydrochloride.

   id

   FG000

   title

   Tivozanib Hydrochloride

2. description

   Participants randomized to this arm received the comparator drug, sorafenib.

   id

   FG001

   title

   Sorafenib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         6

      type

      Randomized but not treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         175

      2. group Id

         FG001

         num Subjects

         175

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         173

      2. group Id

         FG001

         num Subjects

         169

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         6

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 350 participants were randomised and 343 were treated.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice